Here is why biologics are dominating the global anti-inflammatory therapeutics market

For those who are unfamiliar, biologics are macromolecules, consisting of genetically engineered protein derived from living cells. Biologics can be produced by using DNA recombinant technology. They offer targeted therapy and can also be modified depending on patient's need.

According to Research and Markets, owing to their benefits over other small molecules, biologics are dominating the global anti-inflammatory therapeutics market with more than 60% of market share in 2016.